WealthOne’s Charles River Laboratories CRL Stock Holding History

WealthOne’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-41	Closed	-$5K	–	160
2018 Q4	$5K	Buy	+41	New	+$5.13K	﹤0.01%	454

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

WealthOne's CRL Position: Q1 2019 in Review

WealthOne sold out of Charles River Laboratories (CRL) in Q1 2019, closing a stake of 41 shares — an estimated $5K sold.

WealthOne first reported a position in CRL in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 409 funds tracked by Wall St. Rank hold CRL as of Q1 2019.

WealthOne reported no remaining Charles River Laboratories position as of Q1 2019 after selling out during the quarter.
WealthOne sold 41 Charles River Laboratories shares in Q1 2019, an estimated $5K.
WealthOne first reported a position in Charles River Laboratories in Q4 2018 and held it in 1 quarter.
WealthOne's Charles River Laboratories position peaked at $5K in Q4 2018.
409 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2019.

Based on WealthOne's 13F filing for Q1 2019, filed 16 May 2019.